Literature DB >> 15161709

pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance.

Pier Paolo Claudio1, Giuseppe Russo, Christine A C Y Kumar, Corrado Minimo, Antonio Farina, Steve Tutton, Gennaro Nuzzo, Felice Giuliante, Giulia Angeloni, Vellone Maria, Fabio Maria Vecchio, Cristiana Di Campli, Antonio Giordano.   

Abstract

Hepatocarcinoma (HCC) is the fifth most common cancer, with more than one million fatalities occurring annually worldwide. Multiple risk factors are associated with HCC disease etiology, the highest incidence being in patients with chronic hepatitis B virus and hepatitis C virus, although other factors such as genetic makeup and environmental exposure are involved. Multiple genetic alterations including the activation of oncogenes and inactivation of tumor suppressor genes are required for malignancy in human cancers and are correlated with increased stages of carcinogenesis and further tumor progression. In this study of 21 HCC patients, we analyzed pRb2/p130, vascular endothelial growth factor (VEGF), p27((KIP1)), and proliferating cell nuclear antigen as potential HCC molecular biomarkers. In our sample set, we found that p27((KIP1)) was absent. Univariate survival analysis showed that proliferating cell nuclear antigen expression (diffuse staining >50% of positive cells in tumor) was confirmed as a significant HCC prognostic biomarker for determining patient survival agreeing with previous studies (P = 0.0126, log-rank test). Lower pRb2/p130 expression was associated to a borderline P value of inverse correlation with tumor malignancy and to a positive correlation with respect to the time from HCC diagnosis (Spearman coefficient = 0.568; P < 0.05). Conversely, higher VEGF expression was associated with a poor survival (P = 0.0257, log-rank test). We demonstrate for the first time that pRb2/p130 is inversely correlated with VEGF expression and tumor aggressiveness (P < 0.05) in p27((KIP1))-negative HCC patients. pRb2/p130 and VEGF expression are independent from tumor staging, suggesting their possible role as independent prognostic molecular biomarkers in HCC. Furthermore, we have evidence that VEGF together with pRb2/p130 may act as new HCC biomarkers in a p27((KIP1))-independent manner. Additional studies with larger numbers of patient data would allow the use of multivariable techniques and would be able to further identify patients with poorer survival.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161709     DOI: 10.1158/1078-0432.CCR-03-0662

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  7 in total

1.  pRb2/p130 protein in relation to clinicopathological and biological variables in rectal cancers with a clinical trial of preoperative radiotherapy.

Authors:  Satish Babu Moparthi; Viveka Bergman; Gunnar Adell; Sten Thorstensson; Xiao-Feng Sun
Journal:  Int J Colorectal Dis       Date:  2009-07-14       Impact factor: 2.571

2.  Endocan expression correlated with poor survival in human hepatocellular carcinoma.

Authors:  Geng-Wen Huang; Yi-Ming Tao; Xiang Ding
Journal:  Dig Dis Sci       Date:  2008-07-01       Impact factor: 3.199

3.  Identification of genes, including the gene encoding p27Kip1, regulated by serine 276 phosphorylation of the p65 subunit of NF-kappaB.

Authors:  Ratna Chakraborty Prasad; Xiaohui L Wang; Brian K Law; Bradley Davis; Gail Green; Braden Boone; Lauren Sims; Mary Law
Journal:  Cancer Lett       Date:  2008-11-26       Impact factor: 8.679

Review 4.  The clinical utility of the proliferating cell nuclear antigen expression in patients with hepatocellular carcinoma.

Authors:  Shuangshuang Ma; Junsheng Yang; Jinpeng Li; Jinlong Song
Journal:  Tumour Biol       Date:  2015-12-17

5.  Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers.

Authors:  Jia Li; Muhammad Wasif Saif
Journal:  Biologics       Date:  2009-09-15

6.  Low-dose bevacizumab induces radiographic regression of vestibular schwannomas in neurofibromatosis type 2: A case report and literature review.

Authors:  Pengfei Liu; Qingyu Yao; N A Li; Yongliang Liu; Yuguo Wang; Meng Li; Zefu Li; Jianmin Li; Gang Li
Journal:  Oncol Lett       Date:  2016-03-17       Impact factor: 2.967

Review 7.  Hepatocellular Carcinoma: Tumorigenesis and Prediction Markers.

Authors:  Cornelia Braicu; Claudia Burz; Ioana Berindan-Neagoe; Ovidiu Balacescu; Florin Graur; Victor Cristea; Alexandru Irimie
Journal:  Gastroenterology Res       Date:  2009-07-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.